Patents by Inventor Francis C. Maslanka

Francis C. Maslanka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins
    Publication number: 20220089712
    Abstract: Provided herein is a method for producing an antibody, such as an anti-TNF? antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 ?M zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 24, 2022
    Inventors: Marcel Flikweert, Charles Goochee, Francis C. Maslanka, Franciscus Johannes Ignatius Nagel, James R. Ryland, Eugene Schaefer
  • Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins
    Patent number: 11149085
    Abstract: Provided herein is a method for producing an antibody, such as an anti-TNF? antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 ?M zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: October 19, 2021
    Assignees: JANSSEN BIOTECH, INC., JANSSEN BIOLOGICS B.V.
    Inventors: Marcel Flikweert, Charles Goochee, Francis C. Maslanka, Franciscus Johannes Ignatius Nagel, James R. Ryland, Eugene Schaefer
  • Methods for purifying authentic IGF from yeast hosts
    Patent number: 7193042
    Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 20, 2007
    Assignees: Chiron Corporation, Cephalon, Inc.
    Inventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D. Kudrna, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
  • Methods of purifying authentic IGF from yeast hosts
    Patent number: 7071313
    Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: July 4, 2006
    Assignees: Cephalon, Inc., Chiron Corporation
    Inventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D Kudrna, Asuman G. Ozturk, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
  • IGF-I purification process
    Patent number: 6756484
    Abstract: Disclosed is an improved process for obtaining purified, monomeric, intact, correctly-folded insulin-like growth factor-I (also known as somatomedin-C). The improvements, consisting primarily of the addition of an IGF-I unfolding/refolding step and the substitution of a reverse phase chromatography step for a gel filtration chromatography step result in a three-fold increase in final yield. The process includes the following steps, in order: first cation exchange, unfolding/refolding, hydrophobic interaction chromatography, second cation exchange, and reverse phase chromatography.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: June 29, 2004
    Assignees: Cephalon, Inc., Chiron Corporation
    Inventors: Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka, Cynthia Cowgill, Luis G. Juarbe-Osorio, Patricio Riquelme, Glenn Dorin
  • IGF-I purification process
    Patent number: 6207806
    Abstract: Disclosed is an improved process for obtaining purified, monomeric, intact, correctly-folded insulin-like growth factor-I (also known as somatomedin-C). The improvements, consisting primarily of the addition of an IGF-I unfolding/refolding step and the substitution of a reverse phase chromatography step for a gel filtration chromatography step result in a three-fold increase in final yield. The process includes the following steps, in order: first cation exchange, unfolding/refolding, hydrophobic interaction chromatography, second cation exchange, and reverse phase chromatography.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: March 27, 2001
    Assignee: Cephalon Inc.
    Inventors: Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
  • IGF-I purification process
    Patent number: 5650496
    Abstract: Disclosed is an improved process for obtaining purified, monomeric, intact, correctly-folded insulin-like growth factor-I (also known as somatomedin-C). The improvements, consisting primarily of the addition of an IGF-I unfolding/refolding step and the substitution of a reverse phase chromatography step for a gel filtration chromatography step result in a three-fold increase in final yield. The process includes the following steps, in order: first cation exchange, unfolding/refolding, hydrophobic interaction chromatography, second cation exchange, and reverse phase chromatography.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: July 22, 1997
    Assignee: Cephalon, Inc.
    Inventors: Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka